St. Jude Children's Research Hospital
Cutting-Edge Targeted Drug For Cholangiocarcinoma Significantly Extends Patients' Lives!
New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity
World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!
Brigham and Women's Hospital, Harvard Medical School, USA
Royal National Orthopaedic Hospital
